Wellington Shields Capital Management’s Quest Diagnostics DGX Stock Holding History

Wellington Shields Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.4K	Hold	200	–	–	0.01%	316
2026 Q1	$39.2K	Buy	+200	New	+$38.9K	0.01%	299
2025 Q4	–	Sell	-200	Closed	-$38.1K	–	325
2025 Q3	$38.1K	Buy	+200	New	+$35.5K	0.01%	312
2023 Q1	–	Sell	-200	Closed	-$31.3K	–	325
2022 Q4	$31.3K	Sell	200 -900	-82%	-$129K	﹤0.01%	286
2022 Q3	$135K	Hold	1,100	–	–	0.03%	239
2022 Q2	$146K	Sell	1,100 -27,192	-96%	-$3.71M	0.02%	245
2022 Q1	$157K	Buy	+28,292	New	+$3.94M	0.02%	261

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Wellington Shields Capital Management's DGX Position: Q2 2026 in Review

Wellington Shields Capital Management held its Quest Diagnostics (DGX) position steady in Q2 2026 at 200 shares worth $42.4K. The position accounts for 0.01% of the portfolio, ranked #316.

Wellington Shields Capital Management first reported a position in DGX in Q1 2022 and has held it in 7 quarters since. The position peaked at $157K in Q1 2022. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Wellington Shields Capital Management held 200 shares of Quest Diagnostics worth $42.4K as of Q2 2026.
Wellington Shields Capital Management left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.01% of Wellington Shields Capital Management's portfolio in Q2 2026, its #316 holding.
Wellington Shields Capital Management first reported a position in Quest Diagnostics in Q1 2022 and has held it in 7 quarters since.
Wellington Shields Capital Management's Quest Diagnostics position peaked at $157K in Q1 2022.
1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.